Trial Profile
A Non-interventional Biomarker Study in Patients With Non-Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Tumour Histology Eligible for Treatment With Vargatef According to the Approved Label
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jul 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms LUME BioNIS
- Sponsors Boehringer Ingelheim
- 15 Sep 2019 Status changed from active, no longer recruiting to completed.
- 03 Jul 2019 Planned End Date changed from 30 Jun 2019 to 30 Aug 2019.
- 03 Jul 2019 Planned primary completion date changed from 30 Jun 2019 to 30 Aug 2019.